Informed prostate screening, calibrated to your individual risk.

Baseline screening establishes a starting point - both for current risk assessment and as a personal reference for future comparison.

What's included: detailed history covering urinary symptoms, sexual function, family history (particularly cancer history), and any prior PSA results; digital rectal exam (DRE); PSA blood test; urinalysis (to rule out infection or other obvious causes of PSA elevation); risk-factor assessment including ethnicity, age, and family history of related cancers (breast, ovarian, BRCA).

The consultation: 45-60 minutes. Conversation about screening - what it does and doesn't tell us, what next steps would look like based on different result patterns, individual preferences about how to proceed. This isn't just data collection; it's informed decision-making about whether and how to screen.

Timeline: consultation, exam, and blood draw at a single visit. PSA result returns in 1-3 working days. Result discussion with your personal health concierge - by phone, WhatsApp, or follow-up consultation depending on findings.

If baseline is normal: repeat screening at 1-2 year intervals depending on age and risk factors. Your personal health concierge schedules reminders.

If baseline is elevated or borderline: further evaluation pathway - repeat PSA in 4-6 weeks (often eliminates transient elevations), consideration of multiparametric MRI, and structured referral if indicated.

Best suited for first-time prostate screening at age 50+, earlier baseline (40+) with family history, patients resuming screening after a gap, or patients with new urinary symptoms requiring evaluation.

Once a baseline is established, ongoing monitoring is calibrated to individual risk and prior results.

Standard ongoing schedule: average risk with normal baseline - PSA + DRE every 1-2 years; elevated PSA but no biopsy indication - PSA every 4-12 months depending on values; family history - more frequent, typically every 6-12 months; prior biopsy showing no cancer - every 6-12 months for surveillance.

What we look for: PSA velocity (rate of change over time - a rising PSA, even within "normal" range, can be clinically significant); PSA density (PSA divided by prostate volume measured on imaging - higher density suggests higher cancer probability); free PSA ratio (lower free PSA suggests higher cancer probability); changes on DRE (new nodules, change in texture, asymmetry developing over time).

The advantage of consistent monitoring: single PSA values can be misleading - they're influenced by transient factors. Trends over time, in the context of personal baseline, are far more informative. Consistent monitoring through the same clinical team with consistent measurement protocols provides the most reliable signal.

When monitoring triggers escalation: rising PSA velocity (typically >0.75 ng/mL per year, or doubling time <3 years); absolute PSA above age-adjusted threshold; new DRE abnormality; new significant urinary symptoms suggesting cancer rather than BPH.

When monitoring triggers escalation, the next step is typically multiparametric MRI rather than direct biopsy referral.

Multiparametric MRI (mpMRI) has transformed prostate cancer evaluation over the past decade. Instead of taking biopsy samples blindly from PSA-elevated patients, MRI allows targeted assessment - identifying suspicious areas and ruling out cancer in many cases without biopsy.

What mpMRI involves: non-invasive scan with no radiation (MRI uses magnetic fields); typically 30-45 minutes in the scanner; performed at a diagnostic imaging centre (coordinated by Hisential); mild contrast injection in some protocols; some patients find the enclosed space uncomfortable - sedation is available where needed.

What it shows: mpMRI identifies areas within the prostate that have characteristics suspicious for cancer. Results are graded using the PI-RADS classification - PI-RADS 1-2 (very low to low probability of clinically significant cancer); PI-RADS 3 (intermediate/equivocal - often warrants further assessment); PI-RADS 4-5 (high probability of clinically significant cancer - biopsy strongly indicated).

The value of mpMRI in screening: avoid biopsy in many cases (PI-RADS 1-2 results often justify continued monitoring rather than biopsy); target biopsy when needed (MRI findings guide biopsy to specific suspicious areas, increasing detection of clinically significant cancers); reduce diagnosis of clinically insignificant cancers by focusing on areas more likely to harbour aggressive disease.

Hisential's coordination: where mpMRI is appropriate, we discuss the rationale at consultation, coordinate booking at a diagnostic imaging partner centre, receive and review results with you, coordinate onward referral to specialist urology if MRI findings warrant biopsy, and maintain continuity of care throughout.

Insurance and cost: mpMRI cost varies by centre and any contrast used. Some insurance policies cover it under outpatient imaging benefits; others classify it as elective for screening purposes. Your personal health concierge can help with itemised invoicing or arrange direct billing depending on preference.

When screening findings suggest the need for biopsy or further evaluation beyond what Hisential provides, structured referral to specialist urology is initiated. Continuity of care is maintained through your personal health concierge.

When referral is initiated: PI-RADS 4-5 MRI findings; significantly elevated PSA without clear non-cancer explanation; rising PSA velocity beyond age-adjusted thresholds; abnormal DRE findings (palpable nodule, asymmetry, hardness); patient preference for further evaluation.

What happens during referral: Hisential prepares a structured referral summary - screening history, all PSA values, DRE findings, MRI report (if done), risk assessment. Referral to an MMC-registered urology centre - typically at one of several partner centres in Kuala Lumpur. Appointment booking facilitated by your personal health concierge. Records shared securely (with your explicit consent) - your time isn't wasted re-explaining your screening history.

What the urology evaluation typically involves: review of screening findings; repeat DRE if indicated; discussion of biopsy; possible transperineal or transrectal prostate biopsy under image guidance; histopathology of biopsy samples to confirm or exclude cancer; if cancer is found, grading of aggressiveness (Gleason score, ISUP grade).

If biopsy is negative: you can return to Hisential for ongoing monitoring with continued screening at appropriate intervals. The urology referral becomes part of your screening history for future risk assessment.

If biopsy is positive: the urology centre coordinates next steps including additional staging, treatment options discussion (active surveillance, surgery, radiation, hormonal therapy, focal therapies depending on cancer characteristics), and ongoing oncology care. You can choose to maintain Hisential as your general practice for continuity, even as prostate cancer care moves to specialist centres.

Hisential does not perform: prostate biopsy, prostate cancer surgery (prostatectomy), radiation therapy, or hormonal therapy for prostate cancer. These are procedures performed at urology and oncology centres. Hisential's role is structured screening, referral coordination, and continuity of general care.